Regeneron identified the main constraint in drug discovery as a lack of validated targets, not a shortage of advanced therapeutic tools. Their genetics engine was created to explore the 90% of the human genome that was untargeted by existing or experimental medicines, aiming to solve this core problem.
To overcome the scaling challenges of traditional biobanks, Regeneron is pioneering a new model. They partner with companies specializing in aggregating de-identified health records and, separately, with groups handling bio-sampling. This "uncoupled" approach allows them to link massive, independent data streams to achieve unprecedented scale.
Regeneron systematically expands the market for its drugs through "indication expansion." By identifying people in its database with a natural loss-of-function variant for a drug's target, they can scan thousands of diseases to see what other conditions these people are protected from, revealing new therapeutic opportunities.
Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.
While genomics predicts lifelong risk, Regeneron was surprised to discover that proteomics provides a more powerful, dynamic snapshot of health. In many cases, an individual's proteome was more effective at predicting disease outcomes in the next one to five years than their inherited genome, prompting massive investment in the technology.
Regeneron's genetics engine created so many new targets that it revealed a strategic weakness: two-thirds were intracellular and untreatable with its world-class antibody platform. This success forced the company to "reinvent itself" and invest heavily in new modalities like sRNA and gene therapy to capitalize on its own discoveries.
While the industry success rate for drugs entering the clinic is only about 10%, programs with human genetics backing have a 2-3x higher probability of approval. Regeneron reports its success rate is even higher, at four to five times the baseline, due to its strict focus on large-effect genetic signals.